Literature DB >> 23148212

An ultra-specific avian antibody to phosphorylated tau protein reveals a unique mechanism for phosphoepitope recognition.

Heather H Shih1, Chao Tu, Wei Cao, Anne Klein, Renee Ramsey, Brian J Fennell, Matthew Lambert, Deirdre Ní Shúilleabháin, Bénédicte Autin, Eugenia Kouranova, Sri Laxmanan, Steven Braithwaite, Leeying Wu, Mostafa Ait-Zahra, Anthony J Milici, Jo Ann Dumin, Edward R LaVallie, Maya Arai, Christopher Corcoran, Janet E Paulsen, Davinder Gill, Orla Cunningham, Joel Bard, Lydia Mosyak, William J J Finlay.   

Abstract

Highly specific antibodies to phosphoepitopes are valuable tools to study phosphorylation in disease states, but their discovery is largely empirical, and the molecular mechanisms mediating phosphospecific binding are poorly understood. Here, we report the generation and characterization of extremely specific recombinant chicken antibodies to three phosphoepitopes on the Alzheimer disease-associated protein tau. Each antibody shows full specificity for a single phosphopeptide. The chimeric IgG pT231/pS235_1 exhibits a K(D) of 0.35 nm in 1:1 binding to its cognate phosphopeptide. This IgG is murine ortholog-cross-reactive, specifically recognizing the pathological form of tau in brain samples from Alzheimer patients and a mouse model of tauopathy. To better understand the underlying binding mechanisms allowing such remarkable specificity, we determined the structure of pT231/pS235_1 Fab in complex with its cognate phosphopeptide at 1.9 Å resolution. The Fab fragment exhibits novel complementarity determining region (CDR) structures with a "bowl-like" conformation in CDR-H2 that tightly and specifically interacts with the phospho-Thr-231 phosphate group, as well as a long, disulfide-constrained CDR-H3 that mediates peptide recognition. This binding mechanism differs distinctly from either peptide- or hapten-specific antibodies described to date. Surface plasmon resonance analyses showed that pT231/pS235_1 binds a truly compound epitope, as neither phosphorylated Ser-235 nor free peptide shows any measurable binding affinity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23148212      PMCID: PMC3531756          DOI: 10.1074/jbc.M112.415935

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

1.  Diversity screening versus focussed screening in drug discovery.

Authors: 
Journal:  Drug Discov Today       Date:  2000-07       Impact factor: 7.851

Review 2.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

3.  PHENIX: building new software for automated crystallographic structure determination.

Authors:  Paul D Adams; Ralf W Grosse-Kunstleve; Li Wei Hung; Thomas R Ioerger; Airlie J McCoy; Nigel W Moriarty; Randy J Read; James C Sacchettini; Nicholas K Sauter; Thomas C Terwilliger
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2002-10-21

4.  Directed in vitro evolution and crystallographic analysis of a peptide-binding single chain antibody fragment (scFv) with low picomolar affinity.

Authors:  Christian Zahnd; Silvia Spinelli; Béatrice Luginbühl; Patrick Amstutz; Christian Cambillau; Andreas Plückthun
Journal:  J Biol Chem       Date:  2004-01-30       Impact factor: 5.157

5.  The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein.

Authors:  P J Lu; G Wulf; X Z Zhou; P Davies; K P Lu
Journal:  Nature       Date:  1999-06-24       Impact factor: 49.962

6.  Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein.

Authors:  A D Alonso; T Zaidi; M Novak; H S Barra; I Grundke-Iqbal; K Iqbal
Journal:  J Biol Chem       Date:  2001-08-08       Impact factor: 5.157

7.  Methods for the generation of chicken monoclonal antibody fragments by phage display.

Authors:  J Andris-Widhopf; C Rader; P Steinberger; R Fuller; C F Barbas
Journal:  J Immunol Methods       Date:  2000-08-28       Impact factor: 2.303

8.  Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments.

Authors:  H Ksiezak-Reding; W K Liu; S H Yen
Journal:  Brain Res       Date:  1992-12-04       Impact factor: 3.252

9.  Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures.

Authors:  Michael Zemlin; Martin Klinger; Jason Link; Cosima Zemlin; Karl Bauer; Jeffrey A Engler; Harry W Schroeder; Perry M Kirkham
Journal:  J Mol Biol       Date:  2003-12-05       Impact factor: 5.469

10.  C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease.

Authors:  A Abraha; N Ghoshal; T C Gamblin; V Cryns; R W Berry; J Kuret; L I Binder
Journal:  J Cell Sci       Date:  2000-11       Impact factor: 5.285

View more
  31 in total

1.  Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.

Authors:  Sue Townsend; Brian J Fennell; James R Apgar; Matthew Lambert; Barry McDonnell; Joanne Grant; Jason Wade; Edward Franklin; Niall Foy; Deirdre Ní Shúilleabháin; Conor Fields; Alfredo Darmanin-Sheehan; Amy King; Janet E Paulsen; Timothy P Hickling; Lioudmila Tchistiakova; Orla Cunningham; William J J Finlay
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

2.  Phospho-specific antibodies by design.

Authors:  Oda Stoevesandt; Michael J Taussig
Journal:  Nat Biotechnol       Date:  2013-10       Impact factor: 54.908

3.  Directed evolution of a picomolar-affinity, high-specificity antibody targeting phosphorylated tau.

Authors:  Dan Li; Lei Wang; Brandon F Maziuk; Xudong Yao; Benjamin Wolozin; Yong Ku Cho
Journal:  J Biol Chem       Date:  2018-06-13       Impact factor: 5.157

4.  Computationally Designed Cyclic Peptides Derived from an Antibody Loop Increase Breadth of Binding for Influenza Variants.

Authors:  Alexander M Sevy; Iuliia M Gilchuk; Benjamin P Brown; Nina G Bozhanova; Rachel Nargi; Mattie Jensen; Jens Meiler; James E Crowe
Journal:  Structure       Date:  2020-06-30       Impact factor: 5.006

5.  Effect of Phosphorylation and O-GlcNAcylation on Proline-Rich Domains of Tau.

Authors:  Lata Rani; Jeetain Mittal; Sairam S Mallajosyula
Journal:  J Phys Chem B       Date:  2020-03-02       Impact factor: 2.991

6.  The Combining Sites of Anti-lipid A Antibodies Reveal a Widely Utilized Motif Specific for Negatively Charged Groups.

Authors:  Omid Haji-Ghassemi; Sven Müller-Loennies; Teresa Rodriguez; Lore Brade; Hans-Dieter Grimmecke; Helmut Brade; Stephen V Evans
Journal:  J Biol Chem       Date:  2016-03-01       Impact factor: 5.157

Review 7.  Conformational selection in amyloid-based immunotherapy: Survey of crystal structures of antibody-amyloid complexes.

Authors:  Buyong Ma; Jun Zhao; Ruth Nussinov
Journal:  Biochim Biophys Acta       Date:  2016-06-03

8.  Reconciling the structural attributes of avian antibodies.

Authors:  Paul J Conroy; Ruby H P Law; Sarah Gilgunn; Stephen Hearty; Tom T Caradoc-Davies; Gordon Lloyd; Richard J O'Kennedy; James C Whisstock
Journal:  J Biol Chem       Date:  2014-04-15       Impact factor: 5.157

Review 9.  Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.

Authors:  Phuong H Nguyen; Ayyalusamy Ramamoorthy; Bikash R Sahoo; Jie Zheng; Peter Faller; John E Straub; Laura Dominguez; Joan-Emma Shea; Nikolay V Dokholyan; Alfonso De Simone; Buyong Ma; Ruth Nussinov; Saeed Najafi; Son Tung Ngo; Antoine Loquet; Mara Chiricotto; Pritam Ganguly; James McCarty; Mai Suan Li; Carol Hall; Yiming Wang; Yifat Miller; Simone Melchionna; Birgit Habenstein; Stepan Timr; Jiaxing Chen; Brianna Hnath; Birgit Strodel; Rakez Kayed; Sylvain Lesné; Guanghong Wei; Fabio Sterpone; Andrew J Doig; Philippe Derreumaux
Journal:  Chem Rev       Date:  2021-02-05       Impact factor: 60.622

10.  Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders.

Authors:  Brian Spencer; Sven Brüschweiler; Marco Sealey-Cardona; Edward Rockenstein; Anthony Adame; Jazmin Florio; Michael Mante; Ivy Trinh; Robert A Rissman; Robert Konrat; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2018-06-14       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.